Ovid Therapeutics Future Growth
Future criteria checks 2/6
Ovid Therapeutics is forecast to grow earnings and revenue by 38.5% and 47.5% per annum respectively. EPS is expected to grow by 41.1% per annum. Return on equity is forecast to be -1.3% in 3 years.
Key information
38.5%
Earnings growth rate
41.1%
EPS growth rate
Biotechs earnings growth | 31.5% |
Revenue growth rate | 47.5% |
Future return on equity | -1.3% |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 32 | -46 | N/A | -73 | 3 |
12/31/2025 | 46 | -24 | N/A | 0 | 7 |
12/31/2024 | 13 | -51 | N/A | -48 | 8 |
12/31/2023 | 0 | -52 | -46 | -46 | N/A |
9/30/2023 | 0 | -49 | -43 | -43 | N/A |
6/30/2023 | 0 | -49 | -46 | -46 | N/A |
3/31/2023 | 0 | -51 | -49 | -47 | N/A |
12/31/2022 | 2 | -54 | -57 | -55 | N/A |
9/30/2022 | 1 | -68 | -60 | -58 | N/A |
6/30/2022 | 1 | -66 | -58 | -56 | N/A |
3/31/2022 | 1 | -67 | -63 | -62 | N/A |
12/31/2021 | 208 | 120 | 118 | 119 | N/A |
9/30/2021 | 214 | 123 | 116 | 116 | N/A |
6/30/2021 | 221 | 117 | 125 | 126 | N/A |
3/31/2021 | 221 | 110 | 128 | 128 | N/A |
12/31/2020 | 13 | -81 | -52 | -52 | N/A |
9/30/2020 | 7 | -76 | -54 | -54 | N/A |
6/30/2020 | N/A | -76 | -62 | -62 | N/A |
3/31/2020 | N/A | -67 | -57 | -57 | N/A |
12/31/2019 | N/A | -60 | -51 | -51 | N/A |
9/30/2019 | N/A | -56 | -45 | -45 | N/A |
6/30/2019 | N/A | -53 | -46 | -46 | N/A |
3/31/2019 | N/A | -53 | -46 | -45 | N/A |
12/31/2018 | N/A | -52 | -46 | -46 | N/A |
9/30/2018 | N/A | -50 | -44 | -44 | N/A |
6/30/2018 | N/A | -46 | -43 | -43 | N/A |
3/31/2018 | N/A | -44 | -37 | -37 | N/A |
12/31/2017 | N/A | -65 | -32 | -31 | N/A |
9/30/2017 | N/A | -61 | N/A | -28 | N/A |
6/30/2017 | N/A | -58 | N/A | -23 | N/A |
3/31/2017 | N/A | -53 | N/A | -21 | N/A |
12/31/2016 | N/A | -22 | N/A | -18 | N/A |
9/30/2016 | N/A | -18 | N/A | -14 | N/A |
12/31/2015 | N/A | -13 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1OT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1OT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1OT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1OT's revenue (47.5% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 1OT's revenue (47.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1OT is forecast to be unprofitable in 3 years.